A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets in Chinese Patients With Type 2 Diabetes Mellitus and Poor Diet and Exercise Control
Latest Information Update: 22 Apr 2022
At a glance
- Drugs Yogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Easton Biopharmaceuticals
Most Recent Events
- 13 Apr 2022 New trial record